Avanafil use in patients with erectile dysfunction and co-morbidities: Clinical insights from multiple aetiologies - A case series
Abstract
Erectile dysfunction (ED) is a prevalent medical problem affecting men globally, particularly those with co-morbidities such as cardiovascular disease, hypertension, dyslipidaemia and diabetes. This case series aimed to evaluate the effects of avanafil as a treatment option for patients with ED and other co-morbidities. Eight male patients from a family medicine clinic received either 100 mg or 200 mg avanafil based on their clinical indication. Erectile function was assessed using the International Index of Erectile Function-5 (IIEF-5) and Erection Hardness Score. The outcomes included changes in the IIEF-5 score upon avanafil treatment. Our findings demonstrated a significant increase in the 200 mg avanafil treatment group, with the IIEF-5 score increasing from 14.83±9.4 to 24.17±2.6 (P<0.05). However, no significant difference was observed in the 100 mg avanafil treatment group (P=0.7903) and the overall avanafil treatment group (100 mg + 200 mg avanafil; P=0.0501). No adverse events were reported among the patients. Avanafil is considered a potentially safe and effective treatment option for ED, particularly in individuals with co-morbidities.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.